# Safety and Tolerability of Pirfenidone in Acute Pancreatitis

> **NCT05350371** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatitis, Acute

## Interventions

- **DRUG:** Pirfenidone Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05350371
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-02
- **Final completion:** 2027-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05350371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05350371, "Safety and Tolerability of Pirfenidone in Acute Pancreatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05350371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*